PeptiDreamPeptiDream Inc.4587東証プライム医薬品FY ending Dec 2024, consolidated, IFRS
Out of every ¥100 of sales, about ¥45 is left as operating profit. Revenue changed +62.6% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and ending equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | — | —× | 9.5% | —× | — |
| 2021 | 38.5% | 0.35× | 13.5% | 1.07× | 14.5% |
| 2022 | — | —× | 11.8% | —× | — |
| 2023 | 10.6% | 0.43× | 4.6% | 1.65× | 7.5% |
| 2024 | 32.2% | 0.58× | 18.5% | 1.43× | 26.5% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Dec 2021 | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 |
|---|---|---|---|---|---|
| Revenue | 9,422 | 9,366 | 26,852 | 28,712 | 46,677 |
| Cost of revenue | — | 2,358 | — | — | 12,173 |
| Gross profit | — | 7,008 | — | — | 34,504 |
| SG&A | — | 2,590 | — | — | 9,110 |
| Operating income | — | 4,418 | — | — | 21,114 |
| Pretax income | 3,804 | 4,824 | 6,653 | 4,353 | 20,889 |
| Income tax | — | 1,217 | — | — | 5,874 |
| Net income attributable to owners | 2,573 | 3,606 | 7,554 | 3,036 | 15,015 |
| Operating margin | — | 47.2% | — | — | 45.2% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Dec 2021 | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥11.7B | ¥11.7B | ¥5.25B | ¥19.5B | ¥48.1B |
| Total assets | ¥27B | ¥26.6B | ¥63.9B | ¥69.5B | ¥92.8B |
| Net assets | — | ¥25B | — | ¥40.3B | ¥56.8B |
| Share capital | — | ¥3.96B | — | — | ¥3.96B |
| Property, plant and equipment | — | ¥6.44B | — | — | ¥17.5B |
| Intangible assets excluding goodwill | — | ¥75.5M | — | — | — |
| Goodwill | — | — | — | — | ¥8.37B |
| Investment securities | — | ¥4B | — | — | — |
| Current assets | — | ¥13.9B | — | — | ¥57.2B |
| Current liabilities | — | ¥1.27B | — | — | — |
| Total liabilities | — | ¥1.62B | — | — | ¥36B |
| Equity attributable to owners of parent | — | ¥24.8B | — | — | ¥56.8B |
| Retained earnings | — | ¥17.5B | — | — | ¥49.4B |
| Treasury stock | — | -¥620.1M | — | — | -¥1.08B |
EDINET (FSA Japan)
有価証券報告書－第20期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第19期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第16期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第15期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 41 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.